Some bad news from Cambridge-based Tolerx Inc.: The biotechnology company and a partner, GlaxoSmithKline PLC, report their experimental drug for Type 1 diabetes failed to meet the main clinical goal of a late-stage study.
The 272-patient study measured how well newly diagnosed adults were able to improve production of insulin a year after an eight-day course of the treatment, a monoclonal antibody called otelixizumab. The goal was for patients to show a change in a measure of insulin production called C-peptide.
The companies are reviewing the results but have suspended recruitment and dosing of a separate late-stage trial of the treatment.
Otelixizumab, the most advanced drug in their pipeline, is supposed to protect insulin-producing cells in the pancreas from immune system attacks, which hamper the body’s ability to control blood sugar levels.
In 2007, the company and Glaxo allied to develop otelixizumab for Type 1 diabetes and other diseases. has no approved drugs on the market but has several in its pipeline for cancer and other diseases in which the immune system plays a role.
so, we will be tightening our collective belts a little tighter until she or I (prefer both) find a job...
The 272-patient study measured how well newly diagnosed adults were able to improve production of insulin a year after an eight-day course of the treatment, a monoclonal antibody called otelixizumab. The goal was for patients to show a change in a measure of insulin production called C-peptide.
The companies are reviewing the results but have suspended recruitment and dosing of a separate late-stage trial of the treatment.
Otelixizumab, the most advanced drug in their pipeline, is supposed to protect insulin-producing cells in the pancreas from immune system attacks, which hamper the body’s ability to control blood sugar levels.
In 2007, the company and Glaxo allied to develop otelixizumab for Type 1 diabetes and other diseases. has no approved drugs on the market but has several in its pipeline for cancer and other diseases in which the immune system plays a role.
so, we will be tightening our collective belts a little tighter until she or I (prefer both) find a job...
